Clinical spectrum of HTLV-I in south Florida.

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Clinical spectrum of HTLV-I in south Florida.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Apr 15;8(5):466-73. Unique Identifier : AIDSLINE MED/95211539
Harrington WJ Jr; Ucar A; Gill P; Snodgrass S; Sheremata W; Cabral L; Rabin M; Byrne GE Jr; Berger J; Voight W; et al; Department of Medicine, FL 33136, USA.

Abstract: A total of 113 patients with infection due to human T-cell leukemia virus type 1 (HTLV-I) were evaluated at the University of Miami from January 1988 to March 1993. Forty patients were identified with adult T-cell leukemia/lymphoma (ATLL) and 63 with HTLV-I-associated myelopathy (HAM). Three had concomitant ATLL and HAM. Two HAM patients co-infected with human immunodeficiency virus type 1 (HIV-I) developed clonal lymphoproliferative disease during the study period. Patients with ATLL have a poor prognosis; multiple chemotherapy regimens including high-dose cytotoxic agents have been utilized with a small impact on survival. Most of our patients are currently treated with experimental regimens. Rheumatologic or autoimmune illnesses were identified, mostly in HAM patients, and a small number developed immunodeficiencies in the absence of other definable etiologic factors. Most of the patients were immigrants from areas of endemicity in the Caribbean basin, although many Americans were also recognized. HTLV-I/II infection was diagnosed serologically and typed as HTLV-I by polymerase chain reaction (PCR) or a modified Western blot when a DNA sample was not available. In 24 of 40 patients with ATLL, Southern blot hybridization performed on DNA extracted from peripheral blood lymphocytes or tumor tissue demonstrated clonal HTLV-I integration. In South Florida, ATLL and HAM are now seen frequently. Since HTLV-I infection is associated with a 4% lifetime risk of developing ATLL and an additional 0.25% lifetime risk for developing HAM, a large pool of asymptomatically infected individuals must exist here.(ABSTRACT TRUNCATED AT 250 WORDS)

Keywords: Adult Age Distribution Aged Aged, 80 and over Caribbean Region/ETHNOLOGY Female Florida/EPIDEMIOLOGY Human HIV Infections/COMPLICATIONS HIV-1 Immune Tolerance Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated/COMPLICATIONS/ DRUG THERAPY/*EPIDEMIOLOGY Lymphoproliferative Disorders/COMPLICATIONS Male Middle Age Paraparesis, Tropical Spastic/COMPLICATIONS/DRUG THERAPY/ *EPIDEMIOLOGY Polymyositis/COMPLICATIONS Prognosis Risk Factors Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. JOURNAL ARTICLE
950730
M9570910

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .